Dyne Therapeutics Aims for Q1 2027 Launch of Duchenne Muscular Dystrophy Drug
Event summary
- Dyne Therapeutics plans to submit a Biologics License Application for z-rostudirsen in Q2 2026, with a potential U.S. launch in Q1 2027.
- Positive topline results from the DELIVER trial showed a statistically significant change in dystrophin expression and functional improvements in Duchenne muscular dystrophy (DMD) patients.
- The company expects to complete enrollment in the ACHIEVE trial for z-basivarsen in myotonic dystrophy type 1 (DM1) by Q2 2026.
- Dyne has $1.1 billion in cash, with a runway into Q1 2028.
The big picture
Dyne Therapeutics is advancing toward commercialization with its lead programs in Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). The company's FORCE platform aims to deliver functional improvements for patients, positioning it as a key player in the neuromuscular disease space. With significant cash reserves and a clear regulatory path, Dyne is poised to potentially launch its first therapy within the next year.
What we're watching
- Regulatory Approval
- Whether the FDA grants Priority Review and approval for z-rostudirsen on the anticipated timeline.
- Clinical Trial Progress
- The pace at which Dyne completes enrollment in the ACHIEVE trial and initiates Phase 3 trials for both z-rostudirsen and z-basivarsen.
- Pipeline Expansion
- How Dyne advances its four additional development candidates for DMD amenable to skipping of exons 53, 45, 44, and 55.
Related topics